PMC:7534795 / 32767-33808 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T166","span":{"begin":181,"end":186},"obj":"Body_part"},{"id":"T167","span":{"begin":206,"end":227},"obj":"Body_part"},{"id":"T168","span":{"begin":284,"end":289},"obj":"Body_part"},{"id":"T169","span":{"begin":313,"end":324},"obj":"Body_part"},{"id":"T170","span":{"begin":335,"end":342},"obj":"Body_part"},{"id":"T171","span":{"begin":528,"end":533},"obj":"Body_part"},{"id":"T172","span":{"begin":920,"end":925},"obj":"Body_part"}],"attributes":[{"id":"A166","pred":"fma_id","subj":"T166","obj":"http://purl.org/sig/ont/fma/fma67264"},{"id":"A167","pred":"fma_id","subj":"T167","obj":"http://purl.org/sig/ont/fma/fma7161"},{"id":"A168","pred":"fma_id","subj":"T168","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A169","pred":"fma_id","subj":"T169","obj":"http://purl.org/sig/ont/fma/fma82738"},{"id":"A170","pred":"fma_id","subj":"T170","obj":"http://purl.org/sig/ont/fma/fma82743"},{"id":"A171","pred":"fma_id","subj":"T171","obj":"http://purl.org/sig/ont/fma/fma67264"},{"id":"A172","pred":"fma_id","subj":"T172","obj":"http://purl.org/sig/ont/fma/fma67264"}],"text":"A 12-year follow-up study conducted by Wu et al. of 25 patients who recovered from SARS-CoV infection demonstrated patients were affected by various metabolic disturbances altering lipid metabolism and the cardiovascular system. These patients suffered from hyperlipidemia, increased serum concentrations of free fatty acids, abnormal glucose metabolism and other cardiovascular abnormalities (Wu et al., 2017). Considering the genetic similarities between SARS-CoV and SARS-CoV-2, Zhang et al. recently proposed the use of the lipid-lowering statins, which also possess anti-inflammatory properties, as a therapeutic option for patients with COVID-19. This study reported that amongst 13,981 cases of COVID-19, in-hospital use of statins was associated with a lower risk of death and a significantly lower inflammatory response during the entire hospitalization period (Zhang et al., 2020). Thus, suggesting the use of lipid-lowering drugs with anti-inflammatory properties can improve the cardiovascular outcomes in patients with COVID-19."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T58","span":{"begin":206,"end":227},"obj":"Body_part"},{"id":"T59","span":{"begin":284,"end":289},"obj":"Body_part"}],"attributes":[{"id":"A58","pred":"uberon_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/UBERON_0004535"},{"id":"A59","pred":"uberon_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"A 12-year follow-up study conducted by Wu et al. of 25 patients who recovered from SARS-CoV infection demonstrated patients were affected by various metabolic disturbances altering lipid metabolism and the cardiovascular system. These patients suffered from hyperlipidemia, increased serum concentrations of free fatty acids, abnormal glucose metabolism and other cardiovascular abnormalities (Wu et al., 2017). Considering the genetic similarities between SARS-CoV and SARS-CoV-2, Zhang et al. recently proposed the use of the lipid-lowering statins, which also possess anti-inflammatory properties, as a therapeutic option for patients with COVID-19. This study reported that amongst 13,981 cases of COVID-19, in-hospital use of statins was associated with a lower risk of death and a significantly lower inflammatory response during the entire hospitalization period (Zhang et al., 2020). Thus, suggesting the use of lipid-lowering drugs with anti-inflammatory properties can improve the cardiovascular outcomes in patients with COVID-19."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T258","span":{"begin":83,"end":101},"obj":"Disease"},{"id":"T259","span":{"begin":92,"end":101},"obj":"Disease"},{"id":"T260","span":{"begin":258,"end":272},"obj":"Disease"},{"id":"T261","span":{"begin":457,"end":465},"obj":"Disease"},{"id":"T262","span":{"begin":470,"end":478},"obj":"Disease"},{"id":"T263","span":{"begin":643,"end":651},"obj":"Disease"},{"id":"T264","span":{"begin":702,"end":710},"obj":"Disease"},{"id":"T265","span":{"begin":1032,"end":1040},"obj":"Disease"}],"attributes":[{"id":"A258","pred":"mondo_id","subj":"T258","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A259","pred":"mondo_id","subj":"T259","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A260","pred":"mondo_id","subj":"T260","obj":"http://purl.obolibrary.org/obo/MONDO_0021187"},{"id":"A261","pred":"mondo_id","subj":"T261","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A262","pred":"mondo_id","subj":"T262","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A263","pred":"mondo_id","subj":"T263","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A264","pred":"mondo_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A265","pred":"mondo_id","subj":"T265","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"A 12-year follow-up study conducted by Wu et al. of 25 patients who recovered from SARS-CoV infection demonstrated patients were affected by various metabolic disturbances altering lipid metabolism and the cardiovascular system. These patients suffered from hyperlipidemia, increased serum concentrations of free fatty acids, abnormal glucose metabolism and other cardiovascular abnormalities (Wu et al., 2017). Considering the genetic similarities between SARS-CoV and SARS-CoV-2, Zhang et al. recently proposed the use of the lipid-lowering statins, which also possess anti-inflammatory properties, as a therapeutic option for patients with COVID-19. This study reported that amongst 13,981 cases of COVID-19, in-hospital use of statins was associated with a lower risk of death and a significantly lower inflammatory response during the entire hospitalization period (Zhang et al., 2020). Thus, suggesting the use of lipid-lowering drugs with anti-inflammatory properties can improve the cardiovascular outcomes in patients with COVID-19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T33652","span":{"begin":0,"end":1},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T84691","span":{"begin":206,"end":227},"obj":"http://purl.obolibrary.org/obo/UBERON_0004535"},{"id":"T4742","span":{"begin":206,"end":227},"obj":"http://www.ebi.ac.uk/efo/EFO_0000791"},{"id":"T58635","span":{"begin":604,"end":605},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T95845","span":{"begin":759,"end":760},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T6069","span":{"begin":785,"end":786},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"A 12-year follow-up study conducted by Wu et al. of 25 patients who recovered from SARS-CoV infection demonstrated patients were affected by various metabolic disturbances altering lipid metabolism and the cardiovascular system. These patients suffered from hyperlipidemia, increased serum concentrations of free fatty acids, abnormal glucose metabolism and other cardiovascular abnormalities (Wu et al., 2017). Considering the genetic similarities between SARS-CoV and SARS-CoV-2, Zhang et al. recently proposed the use of the lipid-lowering statins, which also possess anti-inflammatory properties, as a therapeutic option for patients with COVID-19. This study reported that amongst 13,981 cases of COVID-19, in-hospital use of statins was associated with a lower risk of death and a significantly lower inflammatory response during the entire hospitalization period (Zhang et al., 2020). Thus, suggesting the use of lipid-lowering drugs with anti-inflammatory properties can improve the cardiovascular outcomes in patients with COVID-19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T250","span":{"begin":181,"end":186},"obj":"Chemical"},{"id":"T251","span":{"begin":313,"end":324},"obj":"Chemical"},{"id":"T252","span":{"begin":319,"end":324},"obj":"Chemical"},{"id":"T253","span":{"begin":335,"end":342},"obj":"Chemical"},{"id":"T255","span":{"begin":528,"end":533},"obj":"Chemical"},{"id":"T256","span":{"begin":543,"end":550},"obj":"Chemical"},{"id":"T257","span":{"begin":731,"end":738},"obj":"Chemical"},{"id":"T258","span":{"begin":920,"end":940},"obj":"Chemical"},{"id":"T259","span":{"begin":920,"end":925},"obj":"Chemical"},{"id":"T260","span":{"begin":935,"end":940},"obj":"Chemical"}],"attributes":[{"id":"A250","pred":"chebi_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/CHEBI_18059"},{"id":"A251","pred":"chebi_id","subj":"T251","obj":"http://purl.obolibrary.org/obo/CHEBI_35366"},{"id":"A252","pred":"chebi_id","subj":"T252","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A253","pred":"chebi_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/CHEBI_17234"},{"id":"A254","pred":"chebi_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/CHEBI_4167"},{"id":"A255","pred":"chebi_id","subj":"T255","obj":"http://purl.obolibrary.org/obo/CHEBI_18059"},{"id":"A256","pred":"chebi_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/CHEBI_87631"},{"id":"A257","pred":"chebi_id","subj":"T257","obj":"http://purl.obolibrary.org/obo/CHEBI_87631"},{"id":"A258","pred":"chebi_id","subj":"T258","obj":"http://purl.obolibrary.org/obo/CHEBI_35679"},{"id":"A259","pred":"chebi_id","subj":"T259","obj":"http://purl.obolibrary.org/obo/CHEBI_18059"},{"id":"A260","pred":"chebi_id","subj":"T260","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"A 12-year follow-up study conducted by Wu et al. of 25 patients who recovered from SARS-CoV infection demonstrated patients were affected by various metabolic disturbances altering lipid metabolism and the cardiovascular system. These patients suffered from hyperlipidemia, increased serum concentrations of free fatty acids, abnormal glucose metabolism and other cardiovascular abnormalities (Wu et al., 2017). Considering the genetic similarities between SARS-CoV and SARS-CoV-2, Zhang et al. recently proposed the use of the lipid-lowering statins, which also possess anti-inflammatory properties, as a therapeutic option for patients with COVID-19. This study reported that amongst 13,981 cases of COVID-19, in-hospital use of statins was associated with a lower risk of death and a significantly lower inflammatory response during the entire hospitalization period (Zhang et al., 2020). Thus, suggesting the use of lipid-lowering drugs with anti-inflammatory properties can improve the cardiovascular outcomes in patients with COVID-19."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T81","span":{"begin":181,"end":197},"obj":"http://purl.obolibrary.org/obo/GO_0006629"},{"id":"T82","span":{"begin":187,"end":197},"obj":"http://purl.obolibrary.org/obo/GO_0008152"},{"id":"T83","span":{"begin":335,"end":353},"obj":"http://purl.obolibrary.org/obo/GO_0006006"},{"id":"T84","span":{"begin":343,"end":353},"obj":"http://purl.obolibrary.org/obo/GO_0008152"},{"id":"T85","span":{"begin":807,"end":828},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"A 12-year follow-up study conducted by Wu et al. of 25 patients who recovered from SARS-CoV infection demonstrated patients were affected by various metabolic disturbances altering lipid metabolism and the cardiovascular system. These patients suffered from hyperlipidemia, increased serum concentrations of free fatty acids, abnormal glucose metabolism and other cardiovascular abnormalities (Wu et al., 2017). Considering the genetic similarities between SARS-CoV and SARS-CoV-2, Zhang et al. recently proposed the use of the lipid-lowering statins, which also possess anti-inflammatory properties, as a therapeutic option for patients with COVID-19. This study reported that amongst 13,981 cases of COVID-19, in-hospital use of statins was associated with a lower risk of death and a significantly lower inflammatory response during the entire hospitalization period (Zhang et al., 2020). Thus, suggesting the use of lipid-lowering drugs with anti-inflammatory properties can improve the cardiovascular outcomes in patients with COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T234","span":{"begin":0,"end":228},"obj":"Sentence"},{"id":"T235","span":{"begin":229,"end":411},"obj":"Sentence"},{"id":"T236","span":{"begin":412,"end":652},"obj":"Sentence"},{"id":"T237","span":{"begin":653,"end":891},"obj":"Sentence"},{"id":"T238","span":{"begin":892,"end":1041},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A 12-year follow-up study conducted by Wu et al. of 25 patients who recovered from SARS-CoV infection demonstrated patients were affected by various metabolic disturbances altering lipid metabolism and the cardiovascular system. These patients suffered from hyperlipidemia, increased serum concentrations of free fatty acids, abnormal glucose metabolism and other cardiovascular abnormalities (Wu et al., 2017). Considering the genetic similarities between SARS-CoV and SARS-CoV-2, Zhang et al. recently proposed the use of the lipid-lowering statins, which also possess anti-inflammatory properties, as a therapeutic option for patients with COVID-19. This study reported that amongst 13,981 cases of COVID-19, in-hospital use of statins was associated with a lower risk of death and a significantly lower inflammatory response during the entire hospitalization period (Zhang et al., 2020). Thus, suggesting the use of lipid-lowering drugs with anti-inflammatory properties can improve the cardiovascular outcomes in patients with COVID-19."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T136","span":{"begin":258,"end":272},"obj":"Phenotype"},{"id":"T137","span":{"begin":313,"end":334},"obj":"Phenotype"},{"id":"T138","span":{"begin":364,"end":392},"obj":"Phenotype"}],"attributes":[{"id":"A136","pred":"hp_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/HP_0003077"},{"id":"A137","pred":"hp_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/HP_0004359"},{"id":"A138","pred":"hp_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/HP_0001626"}],"text":"A 12-year follow-up study conducted by Wu et al. of 25 patients who recovered from SARS-CoV infection demonstrated patients were affected by various metabolic disturbances altering lipid metabolism and the cardiovascular system. These patients suffered from hyperlipidemia, increased serum concentrations of free fatty acids, abnormal glucose metabolism and other cardiovascular abnormalities (Wu et al., 2017). Considering the genetic similarities between SARS-CoV and SARS-CoV-2, Zhang et al. recently proposed the use of the lipid-lowering statins, which also possess anti-inflammatory properties, as a therapeutic option for patients with COVID-19. This study reported that amongst 13,981 cases of COVID-19, in-hospital use of statins was associated with a lower risk of death and a significantly lower inflammatory response during the entire hospitalization period (Zhang et al., 2020). Thus, suggesting the use of lipid-lowering drugs with anti-inflammatory properties can improve the cardiovascular outcomes in patients with COVID-19."}

{"project":"2_test","denotations":[{"id":"33031856-28831119-84038873","span":{"begin":405,"end":409},"obj":"28831119"}],"text":"A 12-year follow-up study conducted by Wu et al. of 25 patients who recovered from SARS-CoV infection demonstrated patients were affected by various metabolic disturbances altering lipid metabolism and the cardiovascular system. These patients suffered from hyperlipidemia, increased serum concentrations of free fatty acids, abnormal glucose metabolism and other cardiovascular abnormalities (Wu et al., 2017). Considering the genetic similarities between SARS-CoV and SARS-CoV-2, Zhang et al. recently proposed the use of the lipid-lowering statins, which also possess anti-inflammatory properties, as a therapeutic option for patients with COVID-19. This study reported that amongst 13,981 cases of COVID-19, in-hospital use of statins was associated with a lower risk of death and a significantly lower inflammatory response during the entire hospitalization period (Zhang et al., 2020). Thus, suggesting the use of lipid-lowering drugs with anti-inflammatory properties can improve the cardiovascular outcomes in patients with COVID-19."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1070","span":{"begin":55,"end":63},"obj":"Species"},{"id":"1071","span":{"begin":115,"end":123},"obj":"Species"},{"id":"1072","span":{"begin":235,"end":243},"obj":"Species"},{"id":"1073","span":{"begin":457,"end":465},"obj":"Species"},{"id":"1074","span":{"begin":470,"end":480},"obj":"Species"},{"id":"1077","span":{"begin":181,"end":186},"obj":"Chemical"},{"id":"1078","span":{"begin":313,"end":324},"obj":"Chemical"},{"id":"1079","span":{"begin":528,"end":533},"obj":"Chemical"},{"id":"1080","span":{"begin":83,"end":101},"obj":"Disease"},{"id":"1081","span":{"begin":258,"end":272},"obj":"Disease"},{"id":"1082","span":{"begin":326,"end":353},"obj":"Disease"},{"id":"1083","span":{"begin":364,"end":392},"obj":"Disease"}],"attributes":[{"id":"A1070","pred":"tao:has_database_id","subj":"1070","obj":"Tax:9606"},{"id":"A1071","pred":"tao:has_database_id","subj":"1071","obj":"Tax:9606"},{"id":"A1072","pred":"tao:has_database_id","subj":"1072","obj":"Tax:9606"},{"id":"A1073","pred":"tao:has_database_id","subj":"1073","obj":"Tax:694009"},{"id":"A1074","pred":"tao:has_database_id","subj":"1074","obj":"Tax:2697049"},{"id":"A1077","pred":"tao:has_database_id","subj":"1077","obj":"MESH:D008055"},{"id":"A1078","pred":"tao:has_database_id","subj":"1078","obj":"MESH:D005227"},{"id":"A1079","pred":"tao:has_database_id","subj":"1079","obj":"MESH:D008055"},{"id":"A1080","pred":"tao:has_database_id","subj":"1080","obj":"MESH:C000657245"},{"id":"A1081","pred":"tao:has_database_id","subj":"1081","obj":"MESH:D006949"},{"id":"A1082","pred":"tao:has_database_id","subj":"1082","obj":"MESH:D044882"},{"id":"A1083","pred":"tao:has_database_id","subj":"1083","obj":"MESH:D002318"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"A 12-year follow-up study conducted by Wu et al. of 25 patients who recovered from SARS-CoV infection demonstrated patients were affected by various metabolic disturbances altering lipid metabolism and the cardiovascular system. These patients suffered from hyperlipidemia, increased serum concentrations of free fatty acids, abnormal glucose metabolism and other cardiovascular abnormalities (Wu et al., 2017). Considering the genetic similarities between SARS-CoV and SARS-CoV-2, Zhang et al. recently proposed the use of the lipid-lowering statins, which also possess anti-inflammatory properties, as a therapeutic option for patients with COVID-19. This study reported that amongst 13,981 cases of COVID-19, in-hospital use of statins was associated with a lower risk of death and a significantly lower inflammatory response during the entire hospitalization period (Zhang et al., 2020). Thus, suggesting the use of lipid-lowering drugs with anti-inflammatory properties can improve the cardiovascular outcomes in patients with COVID-19."}